KeyBanc analyst Matthew Mishan maintained a Buy rating on Avanos Medical (NYSE:AVNS) on Friday, setting a price target of $55, which is approximately 13.22% above the present share price of $48.58.
Mishan expects Avanos Medical to post earnings per share (EPS) of $0.40 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Hold rating of shares in Avanos Medical, with an average price target of $47.67.
The analysts price targets range from a high of $55 to a low of $43.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $185.7 million and a net profit of -$100 thousand. The company's market cap is $2.32 billion.
According to TipRanks.com, KeyBanc analyst Matthew Mishan is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.9% and a 75.00% success rate.
Avanos Medical, Inc. is a medical technology company, which focuses on delivering clinically medical device solutions to improve patients' quality of life. Its portfolio of innovative product offerings focused on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.